{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:50:48Z","timestamp":1789213848432,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PNRR-MAD-2022\u201312375740 M6C"],"award-info":[{"award-number":["PNRR-MAD-2022\u201312375740 M6C"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01812-z","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:01:06Z","timestamp":1780570866000},"page":"3307-3313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"1812_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"issue":"10402","key":"1812_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type\u00a02 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase\u00a03 trial. Lancet. 2023;402(10402):613\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(23)01200-X.","journal-title":"Lancet"},{"issue":"6","key":"1812_CR3","first-page":"649","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(6):649\u201355.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1812_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","volume":"25","author":"F Bellinato","year":"2024","unstructured":"Bellinato F, Maurelli M, Geat D, Girolomoni G, Gisondi P. Managing the patient with psoriasis and metabolic comorbidities. Am J Clin Dermatol. 2024;25(4):527\u201340. https:\/\/doi.org\/10.1007\/s40257-024-00857-0.","journal-title":"Am J Clin Dermatol"},{"key":"1812_CR5","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14281","volume":"33","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Girolomoni G. Metabolic comorbidities and psoriasis: role of weight loss and metabolic control. Dermatol Ther. 2020;33:e13200.","journal-title":"Dermatol Ther"},{"key":"1812_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70208","author":"P Gisondi","year":"2025","unstructured":"Gisondi P, Brigenti N, Bellinato F, Girolomoni G. Tirzepatide in obese patients with psoriasis on biological therapy: is this a window of opportunity? J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70208.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1812_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"1812_CR8","first-page":"159","volume":"164","author":"GS Tirzepatide","year":"2022","unstructured":"Tirzepatide GS. A new anti-obesity medication. Gastroenterology. 2022;164:159.","journal-title":"Gastroenterology"},{"key":"1812_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1014778","volume":"14","author":"A Bensussen","year":"2023","unstructured":"Bensussen A, Torres-Magallanes JA, Roces de \u00c1lvarez-Buylla E. Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. Front Immunol. 2023;14:1014778. https:\/\/doi.org\/10.3389\/fimmu.2023.1014778.","journal-title":"Front Immunol"},{"issue":"7","key":"1812_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40618-022-01755-0","volume":"45","author":"F Bellinato","year":"2022","unstructured":"Bellinato F, Gisondi P, Mantovani A, Girolomoni G, Targher G. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022;45(7):1277\u201388. https:\/\/doi.org\/10.1007\/s40618-022-01755-0.","journal-title":"J Endocrinol Invest"},{"issue":"13","key":"1812_CR11","first-page":"1084","volume":"99","author":"N Goolam Mahyoodeen","year":"2019","unstructured":"Goolam Mahyoodeen N, Crowther NJ, Pillay L, et al. Relationship of visceral fat and adipokines with cardiometabolic diseases in psoriasis. Acta Derm Venereol. 2019;99(13):1084\u201390.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1812_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","volume":"105","author":"JM Carrascosa","year":"2014","unstructured":"Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105(1):31\u201344.","journal-title":"Actas Dermosifiliogr"},{"key":"1812_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/art.70134","author":"JF Merola","year":"2026","unstructured":"Merola JF, Mease P, Kivitz A, et al. Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial. Arthritis Rheumatol. 2026. https:\/\/doi.org\/10.1002\/art.70134.","journal-title":"Arthritis Rheumatol"},{"key":"1812_CR14","unstructured":"Ixekizumab concomitantly administered with tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight (TOGETHER-PsO). Trial summary. Eli Lilly. https:\/\/trials.lilly.com\/en-US\/trial\/533095. Accessed May\u00a08, 2026."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01812-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01812-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01812-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:24:46Z","timestamp":1781753086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01812-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01812-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paolo Gisondi\u00a0has received honoraria as consultant and\/or speaker for AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Eli Lilly, Leo Pharma, Janssen, Novartis, Pfizer, Takeda and UCB. Paolo Gisondi is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Paolo Gisondi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.\u00a0Giampiero\u00a0Girolomoni\u00a0has received honoraria as consultant and\/or speaker for AbbVie, Almira l, Bristol Myers Squibb, Eli Li ly, Leo Pharma, Janssen, Novartis, Pfizer, Samsung and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. The patients gave consent to the anonymous and aggregated publication of baseline general and clinical characteristics, and the outcome measures of the study. The study was exempted from a formal approval from any IRB or ethics board because ixekizumab and tirzepatide have been used for approved label indication in a routine clinical practice and setting of a real-life study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}